lgbtDB

(Q31670)

Revision as of 21:38, 13 November 2024 by Superraptor (talk | contribs) (‎Created a new Item)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Statements

title
Protocol for a randomized controlled trial with a stepped care approach, utilizing PrEP navigation with and without contingency management, for transgender women and sexual minority men with a substance use disorder: Assistance Services [...] (English)
1 reference
stated in
PubMed
abstract
In the United States, most (~ 70%) annual newly diagnosed HIV infections are among substance-using sexual minority men (SMM) and gender minority transgender women (trans women). (English)
source label
BACKGROUND (English)
subsection NLM category
background section
series ordinal
1
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Trans women and SMM are more likely to report or be diagnosed with a substance use disorder (SUD) than their cisgender or heterosexual counterparts and the presence of an SUD substantially increases the risk of HIV infection in both groups. (English)
source label
BACKGROUND (English)
subsection NLM category
background section
series ordinal
2
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Although Pre-Exposure Prophylaxis (PrEP) is highly effective, initiation, adherence, and persistence are exclusively behavioral outcomes; thus, the biomedical benefits of PrEP are abrogated by substance use. (English)
source label
BACKGROUND (English)
subsection NLM category
background section
series ordinal
3
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
SUD is also associated with reduced quality-of-life, and increased overdose deaths, utilization of high-cost healthcare services, engagement in a street economy, and cycles of incarceration. (English)
source label
BACKGROUND (English)
subsection NLM category
background section
series ordinal
4
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
To determine the optimal (considering efficacy and cost-effectiveness) strategy for advancement along the PrEP Care Continuum among trans women and SMM with an SUD. (English)
source label
OBJECTIVE (English)
subsection NLM category
objective section
series ordinal
5
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
This study will implement a randomized controlled trial, evaluating two Stepped Care approaches involving A.S.K.-PrEP vs. standard of care (SOC) to determine optimal intervention strategies for trans women and SMM with an SUD (N = 250; n = 83 trans women; n = 167 SMM) for advancement along the PrEP Care Continuum. (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
6
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Participants will be randomized (3:1) to Stepped Care (n = 187) or SOC (n = 63). (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
7
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Participants in the Stepped Care arm will be assessed at 3-months for intervention response; responders will be maintained in A.S.K.-PrEP, while non-responders will receive added attention to their SUD via Contingency Management (CM). (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
8
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Non-responders will be re-randomized (1:1) to either (a) receive A.S.K.-PrEP + CM, or (b) shift the primary focus to their SUD (CM alone). (English)
source label
METHODS (English)
subsection NLM category
methods section
series ordinal
9
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Recruitment and enrollment began in May 2023. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
10
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Recruitment will span approximately 36 months. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
11
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Data collection, including all follow-up assessments, is expected to be completed in April 2027. (English)
source label
RESULTS (English)
subsection NLM category
results section
series ordinal
12
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
Trans women and SMM with an SUD have the two highest HIV prevalence rates in the United States, which underscores the urgent need for effective measures to develop scalable behavioral interventions that can encourage advancement along the PrEP Care Continuum. (English)
source label
DISCUSSION (English)
subsection NLM category
conclusion section
series ordinal
13
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
To improve public health, researchers must identify scalable and cost-effective behavioral interventions to promote PrEP initiation, adherence, and persistence among trans women and SMM who use substances. (English)
source label
DISCUSSION (English)
subsection NLM category
conclusion section
series ordinal
14
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
This trial has been registered at ClinicalTrials.gov under the number NCT05934877. (English)
source label
TRIAL REGISTRATION (English)
subsection NLM category
background section
series ordinal
15
copyright statement
© 2024. The Author(s). (English)
date copyrighted
2024
rights holder
Q31649
Q31650
Q31652
Q31654
Q31655
Q31656
Q31657
Q31658
Q31659
Q31661
1 reference
stated in
PubMed
date published
9 November 2024
1 reference
stated in
PubMed
date issued
9 November 2024
1 reference
stated in
PubMed
author
volume
19
1 reference
stated in
PubMed
issue
1
1 reference
stated in
PubMed
page(s)
79
1 reference
stated in
PubMed
page start
79
1 reference
stated in
PubMed
 
Retrieved from "https://lgbtdb.wikibase.cloud/w/index.php?title=Item:Q31670&oldid=188668"